These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32337549)

  • 1. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus.
    Gao D; Hao Y; Mu L; Xie W; Fan Y; Ji L; Zhang Z
    Rheumatology (Oxford); 2020 Nov; 59(11):3400-3407. PubMed ID: 32337549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life, remission and low lupus disease activity state in patients with systemic lupus erythematosus.
    Thibault T; Rajillah A; Bourredjem A; Corneloup M; Maurier F; Wahl D; Muller G; Aumaitre O; Sève P; Blaison G; Besancenot JF; Martin T; Magy-Bertrand N; Samson M; Arnaud L; Amoura Z; Devilliers H;
    Rheumatology (Oxford); 2024 May; 63(5):1447-1455. PubMed ID: 37589711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.
    Pawlak-Buś K; Schmidt W; Leszczyński P
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):949-959. PubMed ID: 36808341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low disease activity and remission status of systemic lupus erythematosus in a real-world study].
    Ren L; Zhao C; Zhao Y; Zhou H; Zhang L; Wang Y; Shen L; Fan W; Li Y; Li X; Wang J; Cheng Y; Peng J; Zhao X; Shao M; Li R
    Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):273-278. PubMed ID: 38595244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.
    Parodis I; Lindblom J; Barturen G; Ortega-Castro R; Cervera R; Pers JO; Genre F; Hiepe F; Gerosa M; Kovács L; De Langhe E; Piantoni S; Stummvoll G; Vasconcelos C; Vigone B; Witte T; ; Alarcón-Riquelme ME; Beretta L
    Ann Rheum Dis; 2024 Jun; 83(7):889-900. PubMed ID: 38373843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study.
    Golder V; Kandane-Rathnayake R; Huq M; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand EF;
    Lancet Rheumatol; 2019 Oct; 1(2):e103-e110. PubMed ID: 38229337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
    Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
    Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
    Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
    Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
    Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
    Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
    Pitsigavdaki S; Nikoloudaki M; Garantziotis P; Silvagni E; Repa A; Marangoni A; Flouri I; Avgoustidis N; Parperis K; Fanouriakis A; Govoni M; Sidiropoulos P; Boumpas DT; Bortoluzzi A; Bertsias G
    Ann Rheum Dis; 2024 Mar; 83(4):464-474. PubMed ID: 38233103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting DORIS Remission and LLDAS in SLE: A Review.
    Parra Sánchez AR; van Vollenhoven RF; Morand EF; Bruce IN; Kandane-Rathnayake R; Weiss G; Tummala R; Al-Mossawi H; Sorrentino A
    Rheumatol Ther; 2023 Dec; 10(6):1459-1477. PubMed ID: 37798595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
    Floris A; Piga M; Perra D; Chessa E; Congia M; Mathieu A; Cauli A
    Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
    Hao Y; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Zhang Z
    Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study.
    Golder V; Kandane-Rathnayake R; Li N; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Goldblatt F; Oon S; O'Neill S; Ng K; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Lau CS; Hoi A; Nikpour M; Morand EF;
    Lancet Rheumatol; 2024 Aug; 6(8):e528-e536. PubMed ID: 38876129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
    Morand EF; Abreu G; Furie RA; Golder V; Tummala R
    Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
    Petri M; Magder LS
    Arthritis Rheumatol; 2018 Nov; 70(11):1790-1795. PubMed ID: 29806142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study.
    Fan C; Yang T; Zheng S; Liao X; Xie R; Chen S; Li J
    Front Immunol; 2024; 15():1423035. PubMed ID: 38947321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study.
    Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake BMDB; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Yu D; Karyekar CS; Sing Lau C; Monk JA; Nikpour M; Hoi A; Morand EF;
    Lancet Rheumatol; 2022 Dec; 4(12):e822-e830. PubMed ID: 38261390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LLDAS is an attainable treat-to-target goal in childhood-onset SLE.
    Wahadat MJ; van den Berg L; Timmermans D; van Rijswijk K; van Dijk-Hummelman A; Bakx S; Verkaaik M; Versnel MA; Kamphuis S
    Lupus Sci Med; 2021 Dec; 8(1):. PubMed ID: 34969874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort.
    Tani C; Vagelli R; Stagnaro C; Carli L; Mosca M
    Lupus Sci Med; 2018; 5(1):e000234. PubMed ID: 29531772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.